Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.
Pegaspargase has the same mechanism of action as L-asparaginase derived from Escherichia coli, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from Escherichia coli may cause hypersensitivity in some patients and require frequent administration. The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase. In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- T Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00501826
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 31
- Registration Number
- NCT00440726
- Locations
- 🇨🇦
Sick Kids, Toronto, Ontario, Canada
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
- Conditions
- Recurrent Pediatric ALLAcute Lymphoblastic LeukemiaRefractory Pediatric ALLRelapsed Pediatric ALL
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 9
- Registration Number
- NCT00439296
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- T Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: AsparaginaseOther: Laboratory Biomarker AnalysisDrug: Daunorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MethotrexateDrug: MercaptopurineDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: PrednisoneDrug: NelarabineDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: pegaspargaseDrug: methylprednisoloneDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- Conditions
- L1 Childhood Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaIntermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00381680
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 550
- Registration Number
- NCT00343369
- Locations
- 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪Universitaets - Kinderklinik, Leipzig, Germany
Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Nordic Society for Pediatric Hematology and Oncology
- Target Recruit Count
- 85
- Registration Number
- NCT00192673
- Locations
- 🇩🇰
Department of Pediatrics, Skejby Hospital, Aarhus, Aarhus N, Denmark
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 5377
- Registration Number
- NCT00103285
- Locations
- 🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.